Hamptons Homebuildi...
Health Care: Drugs
Forest Laboratories Inc. (FRX: NYSE)
$38.88 -0.64 | -1.63%
05/24/13 - 01:00 PM ET
Company Cash Flow
| Mar 2013 | Mar 2012 | Mar 2011 | Mar 2010 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | 0.00 | 979.06M | 1.05B | 682.38M |
| Operating Gains/Losses | n.a. | 0.00 | 1.22M | -303.00K |
| Extraordinary Gains / Losses | n.a. | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | n.a. | 63.70M | -59.83M | -26.21M |
| (Increase) Decrease in Inventories | n.a. | 162.17M | 16.40M | -74.24M |
| (Increase) Decrease In Other Current Assets | n.a. | 0.00 | 0.00 | 67.29M |
| (Decrease) Increase In Payables | n.a. | -39.58M | 60.56M | 13.01M |
| (Decrease) Increase In Other Current Liabilities | 0.00 | 78.56M | 29.39M | 238.39M |
| (Increase) Decrease In Other Working Capital | n.a. | -11.00M | -775.00K | 982.00K |
| Other Non-Cash Items | n.a. | 64.23M | 64.24M | 48.51M |
| Net Cash From Continuing Operations | n.a. | 1.44B | 1.15B | 1.02B |
| Net Cash From Discontinued Operations | n.a. | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | 0.00 | 1.44B | 1.15B | 1.02B |
| Sale of Property, Plant & Equipment | n.a. | 0.00 | 0.00 | 0.00 |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | n.a. | 0.00 | 0.00 | 2.14B |
| Purchases of Property, Plant & Equipment | 0.00 | -549.91M | -327.86M | -32.25M |
| Acquisitions | n.a. | -1.26B | 0.00 | 0.00 |
| Purchases of Short-Term Investments | n.a. | 0.00 | 0.00 | -2.64B |
| Other Cash from Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | 0.00 | -1.14B | -369.22M | -529.78M |
| Issuance of Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | n.a. | 9.89M | 2.90M | 1.37M |
| Repayment of Long-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Repurchase of Capital Stock | 0.00 | -859.42M | -508.49M | -16.66M |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | n.a. | 18.00K | -747.00K | 8.87M |
| Net Cash From Financing Activities | 0.00 | -849.51M | -506.34M | -6.42M |
| Effect of Exchange Rate Changes | 0.00 | -9.38M | 1.95M | 40.83M |
| Net Change in Cash & Cash Equivalents | 0.00 | -558.32M | 274.35M | 524.58M |
Portfolios with FRX
- Portfolio NameUser Type
- ProCarl Icahn
- UserMike Fatah's Companies with...
- ContributorStocks With Big Insider Buy...
- ContributorPharmaceutical Short Squeez...
- ContributorEarnings Short Squeeze Play...
- UserSm. Magic July 5 13
- UserLong Term Stock Picks
- UserRikedom
- Userjohnnystocks
- ProRichard Pzena - Pzena Inves...
Latest FRX Headlines from TheStreet
- Forest Rises On Unusually High Volume (FRX) 05.23.13 | 03:05 pm
- July Options Now Available For Forest Laboratories (FRX) 05.20.13 | 01:05 pm
- Forest Reaches New 52-Week High (FRX) 05.14.13 | 11:05 am
- Analysts' Actions: MU BSX CVC FRX 05.10.13 | 08:05 am
- Ironwood's Constipation Drug Sales Disappoint 04.23.13 | 08:04 am
- Today's Drugs Industry Featured Laggard: Forest Laboratories Inc. (FRX) 04.16.13 | 05:04 pm
- Notable Two Hundred Day Moving Average Cross - FRX 04.16.13 | 04:04 pm
- 5 Stocks Pushing The Drugs Industry Downward 04.15.13 | 01:04 pm
- Forest Laboratories Becomes #183 Most Shorted S&P 500 Component, Replacing Allergan 04.10.13 | 03:04 pm
- Ziopharm Considers Options After Drug Failure 03.27.13 | 11:03 am
Press Releases for FRX
- Trevena, Inc. And Forest Laboratories Announce A Collaborative Agreement For Development Of TRV027 For The Treatment Of Acute Heart Failure - PR Newswire 05.09.13 | 06:05 am
- From Perspectives To Struggles, Alzheimer's Family Caregivers Find Strength In Sharing - PR Newswire 02.05.13 | 10:02 am
- Forest Laboratories, Inc. Reports Fiscal Year 2013 Third Quarter Earnings - Business Wire 01.15.13 | 07:01 am
- Forest Laboratories, Inc. Announces Additional Settlement Agreement In BYSTOLIC® Patent Litigation - Business Wire 01.03.13 | 08:01 am
- Forest Laboratories, Inc. Sets Date And Conference Call For Fiscal 2013 Third Quarter Earnings - Business Wire 01.02.13 | 04:01 pm
- FACT SHEET -- Chronic Idiopathic Constipation - Business Wire 12.17.12 | 08:12 am
- Forest Laboratories And Almirall Announce Commercial Availability Of Tudorza™ Pressair™ In US Pharmacies - Business Wire 12.11.12 | 02:12 am
- Forest Laboratories, Inc. To Present Cariprazine Results From A Phase 3 Trial And Two Pharmacology Studies At The American College Of Neuropsychopharmacology (ACNP) Annual Meeting - Business Wire 12.03.12 | 05:12 pm
- Forest Laboratories, Inc. Announces Additional Settlement Agreements In BYSTOLIC® Patent Litigation - Business Wire 11.28.12 | 04:11 pm
- Forest Laboratories Submits New Drug Application For Cariprazine For The Treatment Of Both Schizophrenia And Manic Or Mixed Episodes Associated With Bipolar I Disorder - Business Wire 11.28.12 | 02:11 am
Partner Headlines for FRX
- Cree, Seagate, Sandisk: Why Richie Freeman Likes Them - Investor's Business Daily 04.02.13 | 06:04 pm
- Barron's Recap (3/23/13): World's Best CEOs - Benzinga 03.24.13 | 01:03 pm
- NIRI Appoints Charles Triano to Board of Directors - Benzinga 03.20.13 | 09:03 am
- UPDATE: Credit Suisse Raises PT to $44 on Forest Laboratories on Positive Linzess Survey - Benzinga 03.15.13 | 01:03 pm
- EU Approval for Ironwood's Constella - Analyst Blog - Zacks 11.30.12 | 02:11 pm
- 3 Undervalued Healthcare Stocks Being Sold By Hedge Funds - Seeking Alpha 11.29.12 | 09:11 am
- Data on Pfizer's Lyrica - Analyst Blog - Zacks 11.19.12 | 07:11 pm
- For NovaBay, Simplicity Is The Father Of Invention - Seeking Alpha 11.12.12 | 09:11 am
- Earnings Scorecard: Forest Labs - Analyst Blog - Zacks 10.26.12 | 06:10 pm
- Pre-Market Earnings Report for October 16, 2012 : JNJ, KO, UNH, GS, PNC, STT, GWW, OMC, MAT, FRX, CBSH, DPZ - NASDAQ 10.15.12 | 08:10 pm
